Parathyroid hormone-related protein (PTHrP) is present in fetal and gestational tissues, in which its proposed roles include stimulation of epithelial growth and differentiation, vasodilatation of the uteroplacental vasculature, relaxation of uterine muscle and stimulation of placental calcium transport. The aim of this study was to determine whether the release of PTHrP from gestational tissue explants was tissue specific. In addition, PTHrP concentrations were measured in maternal plasma, umbilical artery and vein plasma, and amniotic fluid from term, uncomplicated pregnancies before the onset of labour. PTHrP was detected in low concentrations in the mother, fetus and placental tissue. Amniotic fluid had ten times the PTHrP concentration compared with that in the maternal or fetal circulations. Using late pregnant human gestational tissues in an in vitro explant system, we found that amnion over placenta, choriodecidua, reflected amnion, and placenta released PTHrP into culture medium in progressively greater amounts over 24 h (P<0·05). This release was not associated with a loss of cell membrane integrity, as indicated by measurement of the intracellular enzyme, lactate dehydrogenase, in the incubation media. After 24 h incubation, the fetal membranes released significantly (P<0·05) greater amounts of PTHrP than did the placenta (placenta 3·7 0·5 pmol PTHrP/g protein). Amnion over placenta released significantly more PTHrP (139·3 43·1 pmol PTHrP/g protein) than did reflected amnion (29·0 8·3 pmol PTHrP/g protein) (P<0·05). This study unequivocally demonstrated that human gestational tissues release PTHrP and it was concluded that the main contributors to PTHrP in amniotic fluid were the human fetal membranes, particularly amnion over placenta. Fetal membrane-derived and amniotic fluid PTHrP are proposed to have stimulatory effects on epithelial growth and differentiation in fetal lung, gut, skin and hair follicles and paracrine effects on placental vascular tone and calcium transport.
Introduction
Parathyroid hormone (PTH)-related protein (PTHrP) was initially described in tumours associated with humoral hypercalcaemia of malignancy (Albright 1941) and has since been localized to several non-malignant tissues, including fetal, reproductive and gestational tissues (Philbrick et al. 1996 , Wysolmerski & Stewart 1998 . PTHrP, PTHrP mRNA and the PTH/PTHrP common receptor have been identified in fetal tissues, uterine smooth muscle, placenta and the fetal membranes, amnion and chorion , Ferguson et al. 1992 , Germain et al. 1992 , Bowden et al. 1994 , Philbrick et al. 1996 , Curtis et al. 1997 , 1998 , Wysolmerski & Stewart 1998 . The tissue localization, temporal expression and in vitro effects of PTHrP in human gestational tissues suggest that this peptide acts locally in an autocrine/ paracrine manner. Evidence also suggests that PTHrP may act as a circulating hormone during fetal life (Daifotis et al. 1992 , Seki et al. 1994 , Papantoniou et al. 1996 .
Both PTHrP and its PTH/PTHrP receptor are essential for fetal development. PTHrP-deficient mice, generated by partial PTHrP gene deletion and homologous recombination, die at birth because of severe skeletal dysplasia (Karaplis et al. 1994 , Kovacs et al. 1996 . Furthermore, mice with homologous deletion of the PTH/PTHrP receptor gene are growth restricted and die at midgestation (Lanske et al. 1996) . The proposed physiological roles for PTHrP in pregnancy include regulation of cellular growth and differentiation (Lee et al. 1995) , vasodilatation of the uteroplacental vasculature (Mandsager et al. 1994 , Macgill et al. 1997 , relaxation of uterine muscle (Dalle et al. 1992 , Paspaliaris et al. 1992 , Williams et al. 1994 and stimulation of placental calcium transport (Care et al. 1990 , Rodda et al. 1988 .
High levels of expression of PTHrP mRNA and of protein are present in human amnion in comparison with placenta and choriodecidua (Ferguson et al. 1992 , Germain et al. 1992 , Curtis et al. 1997 . PTHrP has been shown to be released from cytotrophoblast (Hellman et al. 1992 ) and amnion cell (Germain et al. 1992) cultures. Furthermore, we and others have demonstrated a significant upregulation of PTHrP mRNA and protein in human amnion (Ferguson et al. 1992 , Curtis et al. 1997 and human amniotic fluid (Wlodek et al. 1995) , but not PTH/PTHrP receptor mRNA (Curtis et al. 1998) , at term compared with preterm. Interestingly, PTHrP gene expression and protein in amnion that overlies the fetal surface of the placenta (amnion over placenta) were significantly greater than in amnion that overlies choriodecidua (reflected amnion) (Curtis et al. 1997) . The factors that regulate this differential expression of PTHrP and, indeed, its biological consequences are not known. Greater expression in amnion over placenta may, however, be important in the paracrine regulation of placental vascular tone and calcium transport. The aims of this study, therefore, were to compare the compartmental distribution of PTHrP in the human maternal-fetal unit at term and to investigate, in vitro, whether the release of PTHrP from human gestational tissue explants is tissue specific.
Material and Methods

Reagents
All reagents were obtained from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise stated.
Patients and samples
This project was approved by the Mercy Hospital for Women Research and Ethics Committee and written, informed consent was obtained from participating patients. Samples were collected at term (37-42 weeks gestation) from women undergoing elective caesarean section, before the onset of labour from uncomplicated singleton pregnancies. We have previously demonstrated that PTHrP mRNA expression and protein content in human gestational tissues are not influenced by labour status or route of delivery (Curtis et al. 1997) . Maternal and umbilical artery and vein blood were collected in lithium-heparin tubes (Sarstedt, Ingle Farm, South Australia, Australia) containing aprotonin (final concentration 0·1 mg/ml). Amniotic fluid samples were collected into sterilized plain polypropylene tubes containing aprotonin (Sarstedt). Plasma and amniotic fluids were separated by centrifugation using a Beckman GS-15 centrifuge (Beckman Instruments, Palo Alto, CA, USA) at 3000 r.p.m. for 10 min, aliquoted and stored at 80 C until required for assay for PTHrP immunoreactivity. Placentae and attached fetal membranes were obtained from women undergoing elective caesarean section, before the onset of labour and tissue processing was commenced within 15 min of delivery of the placenta.
Explants
Placental tissue was obtained from a cotyledon. Avascular amnion readily peeled off the underlying chorion. Amnion over placenta and reflected amnion were obtained by blunt dissection. All tissues were placed in ice-cold RPMI (RPMI 1640, Phenol Red Free, Gibco Laboratories, Grand Island, NY, USA). The fetal membranes were cut into 1 cm 3 sections and the placental tissue was teased apart using blunt dissection and placed in RPMI at 37 C in a humidified atmosphere of Carbogen (95% O 2 and 5% CO 2 ) for 1 h. Explants were then blotted dry on sterile filter paper and transferred to 12-well tissue culture plates (Flow Laboratories, McClean, VA, Canada; 150-250 mg wet weight/well). The explants were incubated in 2 ml RPMI containing penicillin G (100 U/ml) and streptomycin (100 µg/ml) for 0, 1, 3, 6 and 24 h in duplicate. At the end of incubations gestational tissues and media were frozen and stored at 20 C until required for processing. Samples of frozen gestational tissues (150-250 mg) were homogenized using a metal blade homogenizer (Ultraturrax, T8 dispersing tool; Jenke and Kunkle GMBH and Co., Staufen, Germany) for 20 s at 24000 r.p.m. in 1 M acetic acid (1:5 w/v). The homogenate was centrifuged at 3000 r.p.m. for 10 min at 4 C. The supernatant was collected and stored at 20 C until required for assay.
PTHrP, lactate dehydrogenase and protein assays
PTHrP in plasma, amniotic fluid and tissues was quantified using a sensitive (2 pmol/l detection limit) and specific N-terminal PTHrP radioimmunoassay as previously described . This radioimmunoassay uses a polyclonal goat antiserum against PTHrP(1-40), against synthetic PTHrP(1-40) and PTHrP(1-84) as standard. There was no cross-reactivity with parathyroid hormone. The intra-and interassay coefficients of variation were 4·8 and 13·6% respectively.
To assess the effects of experimental treatment on cell membrane integrity, release of the intracellular enzyme lactate dehydrogenase (LDH) into incubation medium was determined as previously described (Farrugia et al. 1999) . The protein content of gestational tissues, homogenates and supernatants was determined using the Pierce BCA Protein Assay Kit (Pierce, Rockford, IL, USA) in which protein, via reduction of copper ion, forms a cuprous ion that chelates bicinchoninic acid (BCA), producing a purple-coloured reaction. Bovine serum albumin was used as a reference standard. Twenty-five microlitres homogenate were transferred into a microfuge tube and 25 µl 10 M NaOH added. Samples were boiled for 10 min, cooled and 50 µl 10 M HCl added to neutralize the solution. The intra-and interassay coefficients of variation were 5·0 and 5·5% respectively.
Statistics
Statistical analyses were performed using a commercially available statistical analysis package (Statgraphics, STSC, Rockville, MD, USA). Homogeneity of variance was tested using Bartlett's test (Bartlett 1937) ; the variance was determined to be non-homogenous and all data were logarithmically transformed before further analysis. Data was analysed by either Student's t-test (for comparison between two groups) or multifactorial analysis of variance (ANOVA, for comparisons between three or more groups) followed by Fisher's least significant difference test. Statistical significance was taken as P<0·05. Data are expressed as mean standard error of the mean (...).
Results
Circulating and amniotic fluid PTHrP
PTHrP concentrations in term maternal plasma averaged 2·7 0·4 pmol/l (Table 1 ). There were no significant differences between PTHrP concentrations in arterial cord plasma, venous cord plasma or maternal plasma (Table 1) . However, amniotic fluid PTHrP concentrations (41·8 3·8 pmol/l) were at least tenfold greater than maternal or umbilical plasma values (P<0·0001; Table 1 ).
PTHrP release from gestational tissue explants
PTHrP release from human gestational tissues increased significantly and progressively over 6 h in all tissues (P<0·05; Fig. 1 ) and was increased further at 24 h in reflected amnion, amnion over placenta and choriodecidua (P<0·05; Fig. 1 ). After 24 h of incubation, fetal membrane (amnion over placenta, choriodecidua and reflected amnion) PTHrP release was at least tenfold greater than placental PTHrP release (P<0·05; Fig. 1 , Table 2 ). PTHrP release from amnion over placenta (139·3 43·1 pmol/l) was not significantly different from that of choriodecidua (65·7 20·8 pmol/l), but was significantly greater than that of reflected amnion (29·0 8·3 pmol/l; P<0·05; Table 2 ). The release of PTHrP was not associated with a concomitant release of the intracellular enzyme and marker of cell membrane integrity, LDH (Table 2) . LDH recovery in the incubation medium across all the gestational tissue explants studied, after 24 h of incubation, showed no significant differences and on average was less than 4·0% of total tissue content ( Table 2) .
Discussion
Low concentrations of N-terminal PTHrP were found in the circulation of the mother and the fetus and in placental tissue. Although the literature reports that umbilical cord PTHrP concentrations are greater than maternal values and that the placenta is the source of circulating fetal PTHrP (Daifotis et al. 1992 , Seki et al. 1994 , Papantoniou et al. 1996 , data obtained in this study do not support this proposal. The low levels of PTHrP released from the placenta support our finding of no umbilical venous to arterial gradient and suggest that the placenta is not a major source of circulating PTHrP in the fetus. The findings of the present report are consistent with those of Papantoniou et al. (1996) , who reported low but detectable levels of PTHrP(1-86) that were not different from maternal values. Amniotic fluid PTHrP concentrations from term human pregnancy were found to be approximately 40 pmol/l, which is consistent with other reported values (Dvir et al. 1995 , Wlodek et al. 1995 . As there is no detectable PTHrP in fetal urine (Ferguson et al. 1992 , Wlodek et al. 1995 , it has been suggested that the PTHrP found in amniotic fluid is derived from the amnion. It has also been shown that primary cultures of human amniotic cells secrete PTHrP (Germain et al. 1992) . We therefore used an in vitro explant system to elucidate the gestational tissue source of PTHrP in amniotic fluid and whether there is differential release from human gestational tissues.
Gestational tissue explant systems have been shown to synthesize and release vitamin D3, prorenin, cytokines, prostaglandins and phospholipase A2 (Rubin et al. 1993 , Downing et al. 1996 , Laham et al. 1996 , Simpson et al. 1999 . This study, for the first time, unequivocally demonstrated the release of PTHrP from human gestational tissues. Furthermore, the gestational tissue that released the most PTHrP into the culture medium was the amnion over placenta. Thus the present study confirms that PTHrP is preferentially produced and released from the amnion over placenta. The release of PTHrP observed in this study was not associated with the loss of cell membrane integrity, as indicated by the measurement of the intracellular enzyme LDH. We and others have previously reported that human gestational tissue expression of PTHrP and its mRNA is tissue specific (Ferguson et al. 1992 , Germain et al. 1992 , Curtis et al. 1997 . Furthermore, PTHrP and its mRNA were more abundant in the amnion over placenta than in the reflected amnion, with low values in the placenta (Curtis et al. 1997) . The concentrations of PTHrP released from human amnion and present in amniotic fluid are significantly greater than those found in the fetal or maternal circulation and thus amnion-derived and amniotic fluid PTHrP are likely to have physiological roles during human pregnancy. Paracrine influences of the placenta and choriodecidua may account for the differential expression of PTHrP in amnion over placenta and reflected amnion. Several placental and decidual hormones, cytokines and growth factors have been demonstrated to increase gestational tissue expression and release of PTHrP mRNA (Thiede et al. 1991 , Germain et al. 1992 , Paspaliaris et al. 1992 , Williams et al. 1994 , Dvir et al. 1995 . The high concentrations of PTHrP released from choriodecidua, relative to placenta and reflected amnion, may be the result of contributions from the decidual cells of the maternal endometrium (Thiede et al. 1991 , Paspaliaris et al. 1992 , Williams et al. 1994 .
The specific roles of fetal membrane-derived and amniotic fluid PTHrP have yet to be elucidated, but are recognized as important paracrine components of the fetal-maternal communication system. Amnion-derived PTHrP may be important for amnion cell growth and differentiation or may have paracrine functions in the placenta and in the fetus. PTHrP derived from amnion over placenta may act in a paracrine manner to stimulate placental calcium transport (Rodda et al. 1988 , Care et al. 1990 , Fraher et al. 1992 , Kovacs et al. 1996 and fetalplacental vasodilatation (Mandsager et al. 1994 , Macgill et al. 1997 . Fetal breathing and swallowing would allow amniotic fluid PTHrP to reach the fetal lung and gastrointestinal epithelia respectively. Also, the fetal skin, hair follicles and amnion epithelium are continually bathed in amniotic fluid. Thus amniotic fluid PTHrP could stimulate epithelial growth and differentiation (Kaiser et al. 1994) and may assist in the maturation of these tissues and organs. During fetal lung development, PTHrP is predominantly expressed in bronchial epithelia and alveolar type II cells, whereas its receptor is found in the subepithelial mesenchyme (Hastings et al. 1994 , Rubin et al. 1994 . PTHrP-deficient mice were found to have lung hypoplasia, arrested canalicular development and impaired epithelial cytodifferentiation (Rubin et al. 1997) . PTHrP and its receptor have been shown to be important in the stimulation of lung surfactant phospholipid synthesis (Rubin et al. 1994) . Recently, PTHrP has been found in washings from the intubated tracheae of newborn infants and concentrations increased from preterm to term gestation (Speziale et al. 1998) . Tracheal fluid PTHrP may be derived from the lung itself or from amniotic fluid and may have significant roles in fetal lung development near term.
Rescued PTHrP-knockout mice display a number of skin-related changes, including thinned epidermis, hyperkeratosis, hypoplastic sebaceous glands and a fibrotic dermis (Foley et al. 1998) . In contrast, transgenic mice that overexpress PTHrP display thickened ventral epidermis, acanthosis, papillomatosis and hyperplastic sebaceous glands and cellular dermis (Wysolmerski et al. 1994) . Furthermore, in the PTHrP-overexpressed transgenic mouse model there was failure to initiate follicle development (Wysolmerski et al. 1994 ). These studies demonstrate the important role that amniotic fluid and fetal PTHrP play in the development of hair and skin.
Amniotic fluid PTHrP is in much greater concentrations than that found in either the maternal or fetal circulation. By utilizing an in vitro explant system, we have demonstrated that PTHrP is predominantly released from human fetal membranes, particularly the amnion over placenta. Fetal membrane-derived and amniotic fluid PTHrP thus may have important roles in fetal organ growth and development and placental function. This study provides a model whereby biochemical mechanisms that regulate PTHrP release under normal conditions and in pathological conditions in which fetal growth and placental function are compromised, can be investigated.
